Barclays PLC Acquires 97,565 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Barclays PLC raised its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 367.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,141 shares of the company's stock after purchasing an additional 97,565 shares during the quarter. Barclays PLC owned approximately 0.23% of Fulcrum Therapeutics worth $443,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its stake in shares of Fulcrum Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company's stock valued at $43,000 after buying an additional 4,701 shares in the last quarter. SG Americas Securities LLC grew its position in Fulcrum Therapeutics by 26.5% in the third quarter. SG Americas Securities LLC now owns 33,019 shares of the company's stock worth $118,000 after acquiring an additional 6,926 shares in the last quarter. Profund Advisors LLC acquired a new position in shares of Fulcrum Therapeutics during the 2nd quarter worth $68,000. American Century Companies Inc. raised its holdings in shares of Fulcrum Therapeutics by 13.2% during the 2nd quarter. American Century Companies Inc. now owns 104,371 shares of the company's stock valued at $647,000 after purchasing an additional 12,167 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Fulcrum Therapeutics in the 2nd quarter valued at $82,000. 89.83% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. HC Wainwright reissued a "neutral" rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $9.33.

Fulcrum Therapeutics Price Performance

Shares of Fulcrum Therapeutics stock traded down $0.02 during midday trading on Friday, hitting $3.96. The company had a trading volume of 464,824 shares, compared to its average volume of 995,933. The stock has a market cap of $213.60 million, a PE ratio of -12.77 and a beta of 2.06. Fulcrum Therapeutics, Inc. has a 1-year low of $2.86 and a 1-year high of $13.70. The business's 50 day simple moving average is $4.06 and its two-hundred day simple moving average is $5.45.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.